Analysis of Prostate Tumors Reveals Clues to Cancer’s Aggressiveness Sequencing finds genetic errors common in metastatic tumors
PSA Rising August 4 2018. A comprehensive genetic analysis of metastatic prostate cancer has, for the first time, revealed a number of major ways in which abnormal alterations of the genome propel this aggressive form of the disease.
Using genetic sequencing, scientists revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The multicenter study lays the foundation for finding new ways to treat prostate cancer, particularly for the most aggressive forms of the disease.
August 3, PSA Rising. African American men are more likely to develop prostate cancer than men of any other race and the disease is often more aggressive when diagnosed.
Now, African American touched by prostate cancer are being asked to join an ambitious study to find out why African-American men are at higher risk for developing more aggressive forms of prostate cancer and why they are more likely to die from it.
Palliative care is appropriate at any stage of a cancer diagnosis and can be provided along with curative treatment
August 1, 2018(Source, Rutgers Cancer Institute of New Jersey) When you or a loved one are diagnosed with cancer, it is normal to be overwhelmed by thoughts of prognosis, treatments, and potential complications. Patients wonder how their lives are going to change and whether their quality of life will ever return to normal. Pain and other symptoms, sometimes from the disease and sometimes from the treatments, can have a negative impact on one’s ability to maintain a satisfactory quality of life. Dealing with the diagnosis and learning how to live with cancer requires a team effort and support from a number of professionals.
Palliative care, sometimes referred to as supportive oncology services, is a specialized field of medicine focused on patients with serious illness. The goal is to help maximize quality of life through expert pain and symptom management, improved communication about goals of care and advance care planning, all while providing an extra layer of support while dealing with a serious illness. Ideally, the palliative care team works closely with the oncology team to help ensure that a patient’s quality of life is a focus as they and loved ones deal with all stages of cancer. Continue reading “Palliative Care: Another Level of Support in the Cancer Journey”
Researchers engineer a non-invasive model for monitoring tumor-bone dynamics and response to therapy
August 1, 2018 Scientists at The University of Texas MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer that has spread to the bone in mice so they can better understand and develop treatment for bone metastasis in humans.
“Advanced prostate cancer and other cancers metastasize to the bones, causing resistance to therapy and pain for patients, but it’s not really clear what makes the bone so special to prostate cancer progression,” said Eleonora Dondossola, Ph.D., instructor in Genitourinary Medical Oncology and lead author of a paper in Science Translational Medicine.
“Bone probably provides cues and an attractive microenvironment for cancer cells to grow,” Dr. Dondossola notes, but noninvasive microscopy to study the process in detail is hindered by the thickness of the outer bone blocking the view of inner cavity and bone marrow.
Resistant Cancers Self-Destruct When Exposed to Experimental Drug
May 3, 2018. PSA Rising / UCSF / San Francisco researchers have discovered a promising new line of attack against lethal, treatment-resistant prostate cancer. Analysis of hundreds of human prostate tumors revealed that the most aggressive cancers depend on a built-in cellular stress response to put a brake on their own hot-wired physiology. Experiments in mice and with human cells showed that blocking this stress response with an experimental drug — previously shown to enhance cognition and restore memory after brain damage in rodents — causes treatment-resistant cancer cells to self-destruct while leaving normal cells unaffected.